Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0

作者：

Younes, A. ^{[5
]}

Kuruvilla, J. ^{[4
]}

Pro, B. ^{[5
]}

Wedgwood, A. ^{[5
]}

Li, Z. ^{[3
]}

Drouin, M. ^{[3
]}

Patterson, T. ^{[3
]}

Ward, R. ^{[2
]}

Martell, R. E. ^{[3
]}

Bociek, R. G. ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA

[2] Pharm Corp, Clin Operat, Boulder, CO USA

[3] Drug Dev MethylGene Inc, Montreal, PQ, Canada

[4] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada

[5] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：128 / 128

页数：1

共 50 条

[21] Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). [J].

Garcia-Manero, Guillermo ;

Yang, Allen S. ;

Giles, Francis ;

Faderl, Stefan ;

Ravandi, Farhad ;

Cortes, Jorge ;

Newsome, Willie M. ;

Issa, Jean-Pierre ;

Patterson, Tracy-Ann ;

Dubay, Marja ;

Li, Zuomei ;

Kantarjian, Hagop ;

Martell, Robert E. .

BLOOD, 2006, 108 (11) :552A-553A

[22] Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) [J].

Garcia-Manero, G. ;

Yang, A. S. ;

Klimek, V. ;

Luger, S. ;

Newsome, W. M. ;

Berman, N. ;

Patterson, T. ;

Maroun, C. ;

Li, Z. ;

Ward, R. ;

Martell, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[23] Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). [J].

Carlo-Stella, Carmelo ;

Guidetti, Anna ;

Viviani, Simonetta ;

Bonfante, Valeria ;

Valagussa, Pinuccia ;

Marchiano, Alfonso ;

Crippa, Flavio ;

Zambelli, Stefania ;

Fasola, Cinzia ;

Corradini, Paolo ;

Tarella, Corrado ;

Di Nicola, Massimo ;

Gianni, Alessandro M. .

BLOOD, 2008, 112 (11) :896-897

[24] Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) [J].

DiPersio, John ;

Stadtmauer, Edward A. ;

Nademanee, Auaypom P. ;

Stiff, Patrick ;

Micallef, Ivana ;

Angell, J. ;

Bridger, G. ;

Calandra, Gary .

BLOOD, 2007, 110 (11) :137A-137A

[25] A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL) [J].

Christian, Beth ;

Kopko, Anne ;

Fehniger, Todd A. ;

Bartlett, Nancy L. ;

Blum, Kristie A. .

BLOOD, 2012, 120 (21)

[26] MGCD0103, an oral isotype-selective HDAC inhibitor, has antitumor activity via the induction of the expression of Annexin A1 on AML1/ETO AML in vitro and in vivo [J].

Nameki, Daisuke ;

Masuko, Norio ;

Fujita, Ryouto ;

Sugiura, Shin ;

Yamamoto, Yasuji ;

Minamiguchi, Kazuhisa ;

Matsuo, Ken-Ichi .

CANCER RESEARCH, 2011, 71

[27] A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL) [J].

Christian, Beth ;

Wei, Lai ;

Sexton, Jennifer ;

Jaglowski, Samantha M. ;

Devine, Steven M. ;

Fehniger, Todd A. ;

Wagner-Johnston, Nina ;

Bartlett, Nancy L. ;

Blum, Kristie A. .

BLOOD, 2014, 124 (21)

[28] Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACI), demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL) [J].

Spencer, A. ;

DeAngelo, D. J. ;

Prince, H. M. ;

Bhalla, K. N. ;

Fischer, T. ;

Liu, A. ;

Parker, K. ;

Jalaluddin, M. ;

Scott, J. W. ;

Ottmann, O. G. .

ANNALS OF ONCOLOGY, 2008, 19 :128-128

[29] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors [J].

Siu, L. L. ;

Carducci, M. ;

Chen, E. X. ;

Maclean, M. ;

Pili, R. ;

King, S. ;

Patterson, T. ;

Li, Z. ;

Kalita, A. ;

Reid, G. K. .

EJC SUPPLEMENTS, 2006, 4 (12) :94-95

[30] The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma. [J].

Buglio, Daniela ;

Mamidipudi, Vidya ;

Khaskhely, Noor M. ;

Gloghini, Annunziata ;

Carbone, Antonino ;

Heise, Carla ;

Besterman, Jeffrey M. ;

Martell, Robert E. ;

MacBeth, Kyle J. ;

Younes, Anas .

BLOOD, 2009, 114 (22) :1438-1438

← 1 2 3 4 5 →